Skip to content

Stryker SYK MedSurg and Neurotechnology: — Goodwill

Other segment segments

Orthopaedics
$7.24B

Similar metrics at other companies

Solventum logo
SOLVMedSurg — Goodwill
$4.18B+13.9%
Boston Scientific logo
BSXMedSurg — Goodwill
$7.98B+6.4%
Johnson & Johnson logo
JNJMedical Devices — Goodwill (Note 3)
$33.75B+0.6%
Boston Scientific logo
BSXMedSurg — Goodwill acquired
$274M
Baxter International logo
BAXHealthcare Systems & Technologies — Goodwill
$3.08B-13.4%
Mirion Technologies logo
MIRMedical Segment — Goodwill
$634M0.0%

Other financials

Income statement

See full
Revenue$6.0B+2.6%
Gross profit$3.8B+1.8%
Operating income$936.0M+11.8%
Net income$745.0M+13.9%
EPS (diluted)$1.93+14.2%

Balance sheet

See full
Cash & equivalents$2.9B+24.1%
Total debt$14.4B-15.1%
Total assets$46.3B+0.6%

Cash flow

See full
Operating cash flow$581.0M+132%
CapEx$166.0M+35.0%
Free cash flow$415.0M+227%

Valuation

See full
Market cap$127.55B-13.6%
Enterprise value$139.05B-14.2%
P/E38.2×-12.4×
P/S5.1×-1.2×

Profitability

See full
Gross margin63.8%-0.1pp
Operating margin19.7%+4.4pp
Net margin13.2%+0.9pp
FCF margin18.1%+2.7pp

Returns & leverage

See full
Return on equity32.8%
Debt / equity0.8×
Current ratio2.1×+0.5×

Where this comes from

Reported directly by Stryker in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Stryker’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stryker's medsurg and neurotechnology: — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stryker's medsurg and neurotechnology: — goodwill?
Stryker (SYK) reported medsurg and neurotechnology: — goodwill of $11.95B in Q1 2026.
What does medsurg and neurotechnology: — goodwill mean?
Reflects the intangible asset value recorded when the cost of acquiring businesses within the MedSurg and Neurotechnology segment exceeds the fair value of their identifiable net assets. This balance represents the premium paid for synergies, brand reputation, and market presence. It is subject to periodic impairment testing based on the segment's future performance.